First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
Olga SalameroPau MontesinosChristophe WillekensJosé Antonio Pérez-SimónArnaud PigneuxChristian RécherRakesh PopatCecilia CarpioCésar MolineroCristina MascaróJoaquim VilaM Isabel ArévaloTamara MaesCarlos BuesaFrancesc BoschTim C P SomervaillePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Iadademstat exhibits a good safety profile together with signs of clinical and biologic activity as a single agent in patients with R/R AML. A phase II trial of iadademstat in combination with azacitidine is ongoing (EudraCT No.: 2018-000482-36).